Beijing Biostar Pharmaceuticals Co., Ltd.
Beijing Biostar Pharmaceuticals Co., Ltd.
Explore linked clinical trials.9 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Utidelone Capsules Combined With Doxorubicin for Advanced Soft Tissue Sarcoma | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, neoplasm, sarcoma | Not yet recruiting | Phase 2 | 2026-09-25 | NCT07842276 | |
| Phase I-II Clinical Trial of Utidelone Capsule in Patients With Advanced Solid Tumors | Advanced Solid Tumor | Active, not recruiting | Phase 1 / Phase 2 | 2026-08-27 | NCT05700084 | |
| Efficacy and Safety of Utidelone Capsule and Utidelone Injection in Patients With HER-2 Negative Advanced Breast Cancer | Advanced Breast Cancer | Not yet recruiting | Phase 3 | 2026-07-06 | NCT07684456 | |
| Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer | HER-2 Negative Breast Cancer | Recruiting | Phase 2 | 2026-04-16 | NCT05398861 | |
| Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma | Gastric or Gastroesophageal Junction Adenocarcinoma | Recruiting | Phase 2 / Phase 3 | 2025-11-25 | NCT06841679 | |
| Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, fallopian tube cancer, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, primary peritoneal carcinoma | Not yet recruiting | Phase 2 | 2025-06-30 | NCT07044349 | |
| Utidelone Capsule Monotherapy for Patients with Advanced Solid Tumors | Adnexal Diseases, Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, bile duct cancer, bile duct disorder, bile duct neoplasm, biliary tract disorder, digestive system disorder, digestive system neoplasm, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gastric neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, stomach disorder | Not yet recruiting | Phase 2 | 2024-12-12 | NCT06730581 | |
| Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases | Non-small Cell Lung Cancer Patients with Brain Metastases | Not yet recruiting | Phase 2 | 2024-11-12 | NCT06683703 | |
| Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2023-07-13 | NCT05430399 |